Fusion Antibodies (FAB) Competitors

Fusion Antibodies (LON:FAB) and NetScientific (LON:NSCI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.

Does the media prefer FAB or NSCI?

In the previous week, Fusion Antibodies had 2 more articles in the media than NetScientific. MarketBeat recorded 2 mentions for Fusion Antibodies and 0 mentions for NetScientific. Fusion Antibodies' average media sentiment score of 1.25 beat NetScientific's score of 0.00 indicating that Fusion Antibodies is being referred to more favorably in the media.

Company	Overall Sentiment
Fusion Antibodies	Positive
NetScientific	Neutral

Which has higher valuation & earnings, FAB or NSCI?

NetScientific has lower revenue, but higher earnings than Fusion Antibodies. NetScientific is trading at a lower price-to-earnings ratio than Fusion Antibodies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fusion Antibodies	£1.58M	2.23	-£2.84M	-£0.04	-92.50
NetScientific	£1.45M	8.98	-£2.64M	-£0.11	-494.09

Do analysts prefer FAB or NSCI?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fusion Antibodies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
NetScientific	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Does the MarketBeat Community prefer FAB or NSCI?

NetScientific received 17 more outperform votes than Fusion Antibodies when rated by MarketBeat users. Likewise, 69.61% of users gave NetScientific an outperform vote while only 68.35% of users gave Fusion Antibodies an outperform vote.

Company	Underperform	Outperform
Fusion Antibodies	Outperform Votes 54 68.35%	Underperform Votes 25 31.65%
NetScientific	Outperform Votes 71 69.61%	Underperform Votes 31 30.39%

Do insiders & institutionals believe in FAB or NSCI?

23.0% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 14.7% of NetScientific shares are owned by institutional investors. 11.3% of Fusion Antibodies shares are owned by company insiders. Comparatively, 42.4% of NetScientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is FAB or NSCI more profitable?

Fusion Antibodies has a net margin of -179.67% compared to NetScientific's net margin of -182.91%. NetScientific's return on equity of -13.70% beat Fusion Antibodies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fusion Antibodies	-179.67%	-140.93%	-62.52%
NetScientific	-182.91%	-13.70%	-9.42%

Which has more risk & volatility, FAB or NSCI?

Fusion Antibodies has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, NetScientific has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.

Summary

NetScientific beats Fusion Antibodies on 8 of the 15 factors compared between the two stocks.